Abstract: Ophthalmic compositions including an RKI, a lubricant, a deturgescent agent, a glycosaminoglycan, and water. Methods of using the ophthalmic compositions are also provided.

Abstract: Pharmaceutical kits and use of the kits in the treatment of conditions of the eye, such as dry eye disease, which includes a first composition including a corticosteroid, an immunosuppressant or both a corticosteroid and an immunosuppressant in a pharmaceutically acceptable carrier configured for administration to a subject’s eyes; a second composition including a corticosteroid in a pharmaceutically acceptable carrier configured for administration to a subject’s eyes, where the second composition has a higher concentration of corticosteroid than the first composition; and optionally a lubricating formulation that is pharmaceutical-free. Treatment of dry eye disease includes administering topically to the eyes of a subject suffering from chronic dry eye disease the first composition over a treatment period; and if the subject suffers from an episodic flare up during the treatment period, administering the second composition to substantially alleviate the flare-up.

Abstract: The present disclosure encompasses methods and compositions for extended-release formulations for treating ophthalmic conditions. These formulations comprise a pharmaceutical agent, a cationic polymer, a non-ionic polymer, and a pharmaceutical carrier and are essentially preservative free. The formulations provided herein are particularly useful for sustained and controlled release of drugs and have low side effects.

Abstract: Pharmaceutical compositions and methods for treating ocular disorders in a subject, which include betamethasone or a pharmaceutically acceptable salt thereof at a concentration of 0.01% w/w to 0.08% w/w, mycophenolic acid or a pharmaceutically acceptable salt thereof at a concentration of 0.05% w/w to 0.30% w/w, or both betamethasone and mycophenolic acid or their salts.

Abstract: Pharmaceutical compositions are described, the compositions comprising an immunosuppressant (such as mycophenolic acid) in combination with a very low concentration of a corticosteroid (such as betamethasone) that are capable of treating, preventing, and/or alleviating an ocular surface disease. Methods for fabricating the compositions and using them are also described.

Abstract: A method for delivering fluids, drugs, or medications to a patient's eye, and a system or apparatus for implementing the method, is disclosed. The system and method comprises the use of a corneal sponge to be deposited onto the cornea of the patient's eye while the patient's eyelids are maintained in open positions, and a scleral contact lens is disposed onto the sponge. The scleral lens has an irrigation fluid supply tube fluidically connected thereto for supplying a fluid, drug, or medication to the sponge which is saturated with the fluid, drug, or medication. Once the sponge and lens are inserted onto the corneal region of the eye, the patient's eyelids are closed thereby trapping and maintaining the sponge and lens upon the corneal region of the eye so as to permit the fluid, drug, or medication to be continuously supplied and applied to the corneal region of the eye.

Abstract: A therapeutic lens for the treatment of an epithelial defect comprises a layer of therapeutic material disposed over the stroma and/or Bowman's membrane to inhibit water flow from the tear liquid to the stroma and/or Bowman's membrane, such that corneal deturgescence can be restored to decrease corneal swelling and light scattering. The layer may cover and protect nerve fibers to decrease pain. The layer may comprise an index of refraction to inhibit light scatter from an anterior surface of the stroma and/or Bowman's membrane. The lens may comprise a curved anterior surface that provides functional vision for the patient when the epithelium regenerates. The layer of therapeutic material can be positioned on the eye in many ways, for example with a spray that is cured to adhere the layer to the exposed surface of the stroma and/or Bowman's membrane.

Abstract: A method for delivering fluids, drugs, or medications to a patient's eye, and a system or apparatus for implementing the method, is disclosed. The system and method comprises the use of a corneal sponge to be deposited onto the cornea of the patient's eye while the patient's eyelids are maintained in open positions, and a scleral contact lens is disposed onto the sponge. The scleral lens has an irrigation fluid supply tube fluidically connected thereto for supplying a fluid, drug, or medication to the sponge which is saturated with the fluid, drug, or medication. Once the sponge and lens are inserted onto the corneal region of the eye, the patient's eyelids are closed thereby trapping and maintaining the sponge and lens upon the corneal region of the eye so as to permit the fluid, drug, or medication to be continuously supplied and applied to the corneal region of the eye.

Abstract: The present invention relates generally to a medicinal solution, and more particularly to a medicinal solution which is to be continuously or pulse-delivered for the purpose of treating various ocular diseases, conditions, or maladies, such as keratoconus, infectious keratitis, severe inflammatory conditions, and ocular surface neoplasia. In particular, the medicinal solution comprises the combination of a medication for treating one of the aforenoted or similar diseases, conditions, or maladies, and an anesthetic for rendering the patient comfortable during the treatment procedure.

Abstract: A method for delivering fluids, drugs, or medications to a patient's eye, and a system or apparatus for implementing the method, is disclosed. The system and method comprises the use of a corneal sponge to be deposited onto the cornea of the patient's eye while the patient's eyelids are maintained in open positions, and a scleral contact lens is disposed onto the sponge. The scleral lens has an irrigation fluid supply tube fluidically connected thereto for supplying a fluid, drug, or medication to the sponge which is saturated with the fluid, drug, or medication. Once the sponge and lens are inserted onto the corneal region of the eye, the patient's eyelids are closed thereby trapping and maintaining the sponge and lens upon the corneal region of the eye so as to permit the fluid, drug, or medication to be continuously supplied and applied to the corneal region of the eye.

Abstract: A therapeutic lens for the treatment of an epithelial defect comprises a layer of therapeutic material disposed over the stroma and/or Bowman's membrane to inhibit water flow from the tear liquid to the stroma and/or Bowman's membrane, such that corneal deturgescence can be restored to decrease corneal swelling and light scattering. The layer may cover and protect nerve fibers to decrease pain. The layer may comprise an index of refraction to inhibit light scatter from an anterior surface of the stroma and/or Bowman's membrane. The lens may comprise a curved anterior surface that provides functional vision for the patient when the epithelium regenerates. The layer of therapeutic material can be positioned on the eye in many ways, for example with a spray that is cured to adhere the layer to the exposed surface of the stroma and/or Bowman's membrane.

Abstract: A therapeutic lens for the treatment of an epithelial defect comprises a layer of therapeutic material disposed over the stroma and/or Bowman's membrane to inhibit water flow from the tear liquid to the stroma and/or Bowman's membrane, such that corneal deturgescence can be restored to decrease corneal swelling and light scattering. The layer may cover and protect nerve fibers to decrease pain. The layer may comprise an index of refraction to inhibit light scatter from an anterior surface of the stroma and/or Bowman's membrane. The lens may comprise a curved anterior surface that provides functional vision for the patient when the epithelium regenerates. The layer of therapeutic material can be positioned on the eye in many ways, for example with a spray that is cured to adhere the layer to the exposed surface of the stroma and/or Bowman's membrane.

Abstract: The present invention relates generally to a medicinal solution, and more particularly to a medicinal solution which is to be continuously or pulse-delivered for the purpose of treating various ocular diseases, conditions, or maladies, such as keratoconus, infectious keratitis, severe inflammatory conditions, and ocular surface neoplasia. In particular, the medicinal solution comprises the combination of a medication for treating one of the aforenoted or similar diseases, conditions, or maladies, and an anesthetic for rendering the patient comfortable during the treatment procedure.

Abstract: A method for delivering fluids, drugs, or medications to a patient's eye, and a system or apparatus for implementing the method, is disclosed. The system and method comprises the use of a corneal sponge to be deposited onto the cornea of the patient's eye while the patient's eyelids are maintained in open positions, and a scleral contact lens is disposed onto the sponge. The scleral lens has an irrigation fluid supply tube fluidically connected thereto for supplying a fluid, drug, or medication to the sponge which is saturated with the fluid, drug, or medication. Once the sponge and lens are inserted onto the corneal region of the eye, the patient's eyelids are closed thereby trapping and maintaining the sponge and lens upon the corneal region of the eye so as to permit the fluid, drug, or medication to be continuously supplied and applied to the corneal region of the eye.

Abstract: Ophthalmic compositions including lubricant agent, deturgescent agent, glycosaminoglycan, and water are used to preserve tissue in vitro; for example, ocular tissue, especially a cornea, thereby facilitating subsequent transplant, especially of a complete cornea. Preferably, the ophthalmic composition and tissue are stored at about 0° C. to about 40° C. The ophthalmic solution may be replaced on either a continuous basis or batch exchanged. The volume of ophthalmic solution per individual cornea being preserved would be from about 50 ml to about 500 ml.

Abstract: An accommodative intraocular lens having a soft deformable resilient inner lens portion or core with an exposed anterior inner optic surface and exposed posterior optic surface, the surfaces responsively becoming simultaneously optically steeper and moving axially away from each other. The exposed anterior and posterior surfaces of the inner lens portions may be spherically shaped or aspherically shaped and the shape of the outer lens portion may be spherically or aspherically shaped.

Abstract: Ophthalmic compositions are provided that include a lubricant, a deturgescent agent, a glycosaminoglycan, and water. Methods of using the ophthalmic compositions are also provided.

Abstract: Compositions and systems for topical ophthalmic application, which include an aqueous mixture of steroidal and non-steroidal anti-inflammatory agents in a flowable mucoadhesive polymer, for treating inflammation and inflammatory conditions of the eye.

Abstract: The invention generally relates to shunts in which at least a portion of the body includes a drug.

Abstract: Ophthalmic compositions are provided that include a lubricant, a deturgescent agent, a glycosaminoglycan, and water. Methods of using the ophthalmic compositions are also provided.